Message #14 From:
stevendart Date: October 20, 2009 09:31:27 AM
CYDY - New Press Release
In response to new economic and regulatory realities, CytoDyn, Inc.
(Pink Sheet: CYDY) has made a sea change in its strategy for developing
Cytolin®, the Company’s unique immune therapy for treating early HIV infection
which is under a research study by Massachusetts General Hospital. With 18.8 million
shares outstanding and 25 million available, it is grossly under priced even
with the stock at $10.00 or even $20.00, which at those levels makes the market
cap only $250-500 million. Those figures are ridiculous as those
valuations are typical of start-up bio-tech’s with little proven track
records. Therefore, it may be fair to say that pricing the stock at
$40/share, which is a market cap of $1 billion, are they still under
priced? Who knows, but with those numbers and a worldwide rush to the
doors to curb this growing disease, this company does show that a $5 Billion
valuation is not unrealistic! You can go through the complete press release at:
